首页>投融资
Alpha Cognition
增发
Alpha Cognition Inc. 是一家专注于神经退行性疾病药物开发的生物制药公司,特别是针对阿尔茨海默病和肌萎缩侧索硬化症等疾病。该公司成立于2013年12月31日,注册地位于加拿大.
Alpha Cognition的主要产品线包括治疗阿尔茨海默病的口服缓释药物,这些药物旨在改善轻度至中度阿尔茨海默病患者的生活质量。公司最近开发的新型疗法Zunveyl已获得美国食品药品监督管理局(FDA)的批准。
公司的业务涵盖生物制药、创新药-共价抑制剂和数字疗法-脑科学等多个领域,进一步丰富了其产品线。Alpha Cognition还积极进行融资活动,以支持其研发和市场扩展计划。
Alpha Cognition致力于为神经退行性疾病患者提供有效的治疗方案,以改善其生活质量,并通过不断的技术创新和市场扩展,保持其在生物制药领域的竞争力。
基本信息
-
公司全称Alpha Cognition Inc
-
类型神经退行性疾病药物开发商
-
产业领域药品研发/制造、医药研发/制造、生物药、化学药
-
公司人数15人以下
-
地址VANCOUVER BRITISH COLUMBIA; CA;
-
联系电话1-858-3444375
-
邮箱info@alphacognition.com
-
成立时间2014-01-01
投融资
-
2024-11-13增发5000万美元未透露
-
2024-11-12上市未透露未透露
-
2024-11-11退市未透露未透露
-
2024-09-24上市后再融资454.5万美元未透露
-
2024-01-19上市后再融资845万美元未透露
-
2023-11-08上市后再融资270万美元未透露
-
2023-02-15上市后再融资500万美元未透露
-
2021-08-20上市未透露未透露
- 加载更多
相关投融资企业
收并购
Advanced Accelerator Applications (AAA), a subsidiary of Novartis AG, founded in 2002 by Italian academics as a spin-off from the European Organization for Nuclear Research (CERN, Switzerland), develops diagnostic and therapeutic products, including PET radiopharmaceuticals. The company focuses on Personalized Medicine, aimed at providing treatments tailored to a patient's profile and disease, using predictive, preventive and personalized procedures. In January 2018, AAA became a subsidiary of Novartis AG.In July 2016, the company opened its first US manufacturing facility in Millburn, NJ. The Millburn plant served as a distribution center for NETSPOT.In April 2014, AAA opened a new office in the US located at Manhattan, NY. At that time, the company planned to set up a new manufacturing facility in the US.In February 2012, AAA planned to build a radiopharmaceutical facility in Murcia, Spain. The facility was expected to be completed within 18 months.By December 201
B轮
Veradermics Inc (美国):Veradermics是一家位于美国的生物技术公司,专注于皮肤健康和美容产品的研发。公司的主要研究领域包括皮肤再生、抗衰老和皮肤修复。Veradermics利用其专有的生物材料和技术平台,开发了一系列高效的皮肤护理产品。公司的产品线包括抗衰老面霜、皮肤修复凝胶和皮肤再生面膜等。
B轮
Qnovia, formerly known as Respira Technologies, is focused on developing inhaled drug delivery platforms to deliver drugs for nicotine replacement therapy and cardiopulmonary diseases.In September 2022, the company changed its name from Respira Technologies to Qnovia.In September 2022, the company raised USD 17M in Series A funding led by Blue Ledge Capital, DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures,